<html><head><style>body {
   color: black;
}
</style></head><body><html><head><style>body {
   color: black;
}
</style></head><body><p><strong>Citations</strong></p>
<p>Hur, Ji-Yeun.\u03b3-Secretase in Alzheimer\u2019s Disease.\ <em>Experimental &amp; Molecular Medicine</em>, vol. 54, no. 10, 2022, doi:10.1038/s12276-022-00754-8. Accessed 2024.<br>Zoltowska, Katarzyna Marta, et al. \Alzheimer\u2019s Disease Linked A\u03b242 Exerts Product Feedback Inhibition on \u03b3-Secretase Impairing Downstream Cell Signaling.\ <em>eLife</em>, vol. 2024, 2024, doi:10.7554/eLife.90690. Accessed 2024.</p>
<p>Zoltowska, Katarzyna Marta, et al. \Alzheimer\u2019s Disease Linked A\u03b242 Exerts Product Feedback Inhibition on \u03b3-Secretase Impairing Downstream Cell Signaling.\ <em>bioRxiv</em>, 2024, doi:10.1101/2023.08.02.551596. Accessed 2024.</p>
<p>Linfeng, Sun, et al. \Analysis of 138 Pathogenic Mutations in Presenilin-1 on the In Vitro Production of A\u03b242 and A\u03b240 Peptides by \u03b3-Secretase.\ <em>Proceedings of the National Academy of Sciences of the United States of America</em>, vol. 114, no. 24, 2017, pp. 6364-6370. doi:10.1073/pnas.1618657114. Accessed 2024.</p>
<h2 id="working-hypothesis">Working Hypothesis</h2>
<p>The A\u03b3-secretase complex plays a pivotal role in the pathogenesis of Alzheimer\u2019s disease (AD) through its involvement in the cleavage of amyloid precursor protein (APP), leading to the generation of amyloid-beta (A\u03b2) peptides, particularly A\u03b242. The hypothesis posits that dysregulation of \u03b3-secretase activity contributes to the accumulation of A\u03b242, which is a key driver of amyloid plaque formation and neurotoxicity in AD. A\u03b242 has been shown to inhibit \u03b3-secretase activity, creating a feedback loop that exacerbates the accumulation of APP-CTFs and disrupts essential signaling pathways, particularly those involving Notch signaling, which is crucial for neuronal health and memory formation (Zoltowska et al., 2024; Hur, 2022).The unmet medical need for AD treatment is significant, as current therapies primarily focus on symptomatic relief rather than addressing the underlying pathophysiology. There is a critical need for disease-modifying therapies that target the amyloid cascade and restore normal \u03b3-secretase function without the adverse effects associated with complete inhibition. This could potentially mitigate the neurotoxic effects of A\u03b2 accumulation and improve cognitive function in affected individuals (Zoltowska et al., 2024).</p>
<h2 id="unmet-medical-need">Unmet Medical Need</h2>
<p>Despite the approval of therapies like aducanumab, which target A\u03b2 aggregates, there remains a substantial gap in effective treatments that address the multifactorial nature of AD. Current approaches often lead to adverse effects due to the indiscriminate inhibition of \u03b3-secretase, which is involved in cleaving multiple substrates, including Notch, essential for neuronal signaling (Hur, 2022). Therefore, there is a pressing need for more selective modulators of \u03b3-secretase that can decrease A\u03b242 levels while preserving its other physiological functions.</p>
<h2 id="suitability-for-combination-therapy">Suitability for Combination Therapy</h2>
<p>Given the complexity of AD pathogenesis, combination therapies targeting multiple pathways may offer a more effective strategy. For instance, combining \u03b3-secretase modulators with agents that enhance A\u03b2 clearance or target tau pathology could provide synergistic effects, addressing both amyloid and tau-related neurodegeneration. Such an approach could optimize therapeutic outcomes and minimize side effects associated with monotherapy (Zoltowska et al., 2024).</p>
<h2 id="predictive-biomarkers">Predictive Biomarkers</h2>
<p>The identification of predictive biomarkers for AD progression is crucial for developing targeted therapies. Elevated levels of A\u03b242 in cerebrospinal fluid (CSF) and its accumulation in brain tissue are well-established biomarkers for AD. Additionally, the concentration of A\u03b242 in synaptic compartments has been shown to correlate with \u03b3-secretase inhibition, suggesting that monitoring these levels could provide insights into disease progression and treatment efficacy (Zoltowska et al., 2024).</p>
<h2 id="clinical-relevance-of-existing-biomarkers">Clinical Relevance of Existing Biomarkers</h2>
<p>Existing biomarkers, such as the A\u03b242/A\u03b240 ratio and the presence of amyloid plaques on PET scans, are instrumental in diagnosing AD and monitoring disease progression. However, the clinical relevance of these biomarkers extends beyond diagnosis; they can also inform treatment decisions and the likelihood of therapeutic response. Understanding the dynamics of A\u03b242 production and A\u03b3-secretase activity may facilitate the development of more tailored interventions, ultimately improving patient outcomes (Linfeng et al., 2017; Hur, 2022).</p>
<hr>
<h3 id="output_ratt">output_ratt</h3>
<p><strong>Citations</strong>
<strong>Yang, S., Sadequl, I., Makoto, M., and Zou, K. (2024). 
-Presenilin: A Multi-Functional Molecule in the Pathogenesis of Alzheimer\u2019s Disease and Other Neurodegenerative Diseases.\ <em>International Journal of Molecular Sciences</em>, vol. 25, no. 3, p. 1757. DOI: 10.3390/ijms25031757. Accessed 2024.</strong></p>
<h2 id="clinical-target-rationale-for-gamma-secretase-in-alzheimer-s-disease">Clinical Target Rationale for Gamma Secretase in Alzheimer&#39;s Disease</h2>
<h3 id="relevance-of-target-location-to-disease-biology">Relevance of Target Location to Disease Biology</h3>
<p>Gamma secretase (GSEC) is a multi-subunit protease complex that plays a crucial role in the cleavage of type I transmembrane proteins, including the amyloid precursor protein (APP). The cleavage of APP by GSEC leads to the generation of amyloid-beta (A\u03b2) peptides, which are central to the pathogenesis of Alzheimer&#39;s disease (AD). The production of A\u03b2, particularly the aggregation-prone A\u03b242 variant, is a key feature of AD pathology, resulting in amyloid plaque formation (Yang et al., 2024). </p>
<h3 id="alteration-of-target-expression-in-human-disease">Alteration of Target Expression in Human Disease</h3>
<p>In Alzheimer&#39;s disease, mutations in the presenilin genes (PSEN1 and PSEN2), which are critical components of the GSEC complex, lead to altered gamma secretase activity. These mutations are associated with an increased production of A\u03b242 over A\u03b240, thereby promoting amyloid plaque formation. Over 200 mutations in presenilin have been linked to familial AD, with approximately 90% of familial cases attributed to these genetic alterations (Yang et al., 2024). </p>
<h3 id="involvement-of-target-in-physiological-processes-relevant-to-disease">Involvement of Target in Physiological Processes Relevant to Disease</h3>
<p>GSEC is essential not only for APP processing but also for the cleavage of other substrates involved in critical cellular processes, such as Notch signaling. The dysregulation of GSEC activity due to presenilin mutations disrupts these processes, contributing to synaptic dysfunction, neuroinflammation, and ultimately neuronal death, which are hallmarks of AD (Yang et al., 2024). </p>
<h3 id="identified-phenotypes-and-genotypes-for-the-target">Identified Phenotypes and Genotypes for the Target</h3>
<p>Mutations in presenilin, particularly PSEN1, lead to distinct phenotypes of early-onset familial AD, characterized by cognitive decline and the presence of amyloid plaques. The genetic variations in presenilin have been shown to correlate with the severity and onset of AD symptoms, reinforcing the significance of this target in disease pathology (Yang et al., 2024).</p>
<h3 id="genetic-link-between-target-and-disease">Genetic Link Between Target and Disease</h3>
<p>The genetic link between presenilin and Alzheimer&#39;s disease is well-established, with numerous studies documenting how mutations in PSEN1 and PSEN2 lead to altered gamma secretase function. This disruption results in an imbalance in A\u03b2 production, favoring the formation of the more toxic A\u03b242 peptide, which is directly implicated in the development of amyloid plaques (Yang et al., 2024). </p>
<h3 id="evidence-from-clinical-studies-and-tools">Evidence from Clinical Studies and Tools</h3>
<p>Clinical trials targeting gamma secretase have faced challenges, with drugs such as semagacestat and avagacestat being discontinued due to adverse effects, including cognitive decline. However, ongoing research continues to explore the potential of refining GSEC inhibitors and developing personalized medicine approaches based on specific presenilin mutations (Yang et al., 2024). The use of CRISPR-Cas9 technology also shows promise in selectively disrupting PSEN1 mutations, further supporting the genetic link to AD (Yang et al., 2024).</p>
<h3 id="required-target-modulation-for-treatment">Required Target Modulation for Treatment</h3>
<p>Effective treatment strategies for Alzheimer&#39;s disease will require careful modulation of gamma secretase activity. The goal is to reduce the production of toxic A\u03b2 peptides while preserving the essential functions of GSEC in processing other substrates. This balance is critical to avoid unintended consequences that could arise from complete inhibition of gamma secretase activity (Yang et al., 2024). </p>
<hr>
<h3 id="challenges-for-the-drug-discovery-program-related-to-gamma-secretase-as-a-target-in-alzheimer-s-disease">Challenges for the Drug Discovery Program Related to Gamma Secretase as a Target in Alzheimer&#39;s Disease</h3>
<p><strong>Citations</strong></p>
<p> <em><em>Hur, Ji-Yeun. \u03b3-Secretase in Alzheimer\u2019s Disease.\ </em>Experimental &amp; Molecular Medicine</em>, vol. 54, no. 9, 2022, Article 9076685, doi:10.1038/s12276-022-00754-8. Accessed 2024.</p>
<p><em><em>Luo, Joanna E., and Yue-Ming Li. \Turning the Tide on Alzheimer\u2019s Disease: Modulation of \u03b3-Secretase.\ </em>Cell &amp; Bioscience</em>, vol. 12, no. 1, 2022, pp. 1-20. doi:10.1186/s13578-021-00738-7. Accessed 2024.</p>
<p><em><em>Svedru\u017ei\u0107, \u017deljko M., Vesna \u0160endula Jengi\u0107, and Lucija Ostoji\u0107. \The Binding of Different Substrate Molecules at the Docking Site and the Active Site of \u03b3-Secretase Can Trigger Toxic Events in Sporadic and Familial Alzheimer\u2019s Disease.\ </em>International Journal of Molecular Sciences</em>, vol. 24, no. 3, 2023, Article 1835. doi:10.3390/ijms24031835. Accessed 2024.</p>
<p><strong>Developing Small Molecule Modulators or Inhibitors of Gamma Secretase</strong> Developing small molecule modulators or inhibitors of gamma secretase (GSEC) presents significant challenges due to the complex nature of this multi-subunit protease involved in the production of amyloid-beta (A\u03b2) peptides. While gamma secretase inhibitors (GSIs) have shown the ability to reduce A\u03b2 production, their nonselective inhibition of Notch signaling has led to severe side effects, including impaired cognition and increased cancer risk (Hur, 2022). This necessitates the development of more selective gamma secretase modulators (GSMs) that can alter the processing of APP without fully inhibiting GSEC activity, thereby sparing Notch processing and potentially reducing adverse effects (Luo and Li, 2022).</p>
<p><strong>Information Driven Approach (IDA) Strategy</strong> </p>
<p>An information-driven approach (IDA) based on available small molecules is indeed possible and could be beneficial in identifying more selective modulators. This strategy would involve leveraging high-resolution structural studies of gamma secretase to inform the design of small molecules that can selectively modulate its activity (Luo and Li, 2022). Understanding the binding sites and interactions within the gamma secretase complex is crucial for developing effective GSMs that can enhance the production of shorter, less toxic A\u03b2 peptides while minimizing the formation of longer, aggregation-prone forms (Hur, 2022). </p>
<p><strong>Known Small Molecular Modulators</strong> </p>
<p>Several small molecular modulators of gamma secretase have been identified, including NSAID-derived GSMs and more recent non-NSAID-derived compounds. First-generation GSMs, such as ibuprofen and indomethacin, have demonstrated efficacy in lowering A\u03b242 levels without affecting Notch cleavage (Luo and Li, 2022). The second-generation GSMs, such as E2012, have also shown promise in clinical settings by selectively reducing A\u03b2 levels (Luo and Li, 2022). However, challenges remain in improving their potency and brain penetration while mitigating side effects. </p>
<p><strong>Required Inhibitors and Modulators for Target Modulation</strong> </p>
<p>To effectively modulate gamma secretase in Alzheimer&#39;s disease, a combination of inhibitors, antagonists, and allosteric modulators will be necessary. Positive allosteric modulators (PAMs) may enhance GSEC&#39;s carboxypeptidase-like activity, thus promoting the generation of shorter A\u03b2 peptides. Conversely, negative allosteric modulators (NAMs) could be designed to inhibit the production of longer, more pathogenic A\u03b2 forms (Svedru\u017ei\u0107 et al., 2023). The development of competitive inhibitors that mimic protective genetic mutations, such as the A673T mutation, could also provide a novel therapeutic strategy (Svedru\u017ei\u0107 et al., 2023). </p>
<p><strong>Patient Response to Therapy</strong> </p>
<p>Patients who would likely respond to therapy targeting gamma secretase modulation include those in the early stages of Alzheimer&#39;s disease, particularly those with elevated amyloid levels as indicated by PET imaging. Identifying amyloid-positive individuals will be crucial for the effective application of GSMs and other A\u03b2-targeted therapies (Luo and Li, 2022). Furthermore, understanding the genetic and biochemical profiles of patients may help tailor treatments to enhance efficacy. </p>
<p><strong>Desirability and Commercial Viability of the Mode of Action</strong> </p>
<p>The proposed mode of action for gamma secretase modulation is both desirable and commercially viable in a clinical setting. By selectively altering the processing of APP to favor the production of shorter, less toxic A\u03b2 peptides, GSMs could potentially mitigate the neurotoxic effects associated with Alzheimer\u2019s disease while minimizing adverse effects related to Notch signaling inhibition (Hur, 2022). This approach aligns well with the current trend toward precision medicine, where therapies are tailored to the specific pathophysiological mechanisms of individual patients. </p>
<p><strong>Advantages and Disadvantages of Different Therapeutic Modalities</strong> </p>
<p>Various therapeutic modalities present distinct advantages and disadvantages in targeting gamma secretase.  </p>
<ul>
<li><p><strong>Antibodies</strong>: While they can provide high specificity and efficacy, their large size may limit brain penetration and necessitate parenteral administration.      - <strong>Small Molecules</strong>: These offer the potential for oral administration and better brain penetration, but challenges in selectivity and off-target effects remain significant (Luo and Li, 2022). </p>
</li>
<li><p><strong>Antisense Oligonucleotides</strong>: These can specifically target mRNA, potentially reducing A\u03b2 production at the transcriptional level, but delivery to the central nervous system (CNS) is a critical hurdle. </p>
</li>
<li><p><strong>PROTACs and Molecular Glue</strong>: These emerging modalities offer innovative approaches to target protein degradation, which may provide a way to selectively eliminate pathological proteins, including those involved in A\u03b2 aggregation.</p>
</li>
<li><p><strong>Peptide Macrocycles</strong>: These can offer high specificity and affinity but may face challenges in terms of stability and bioavailability. In conclusion, while the development of gamma secretase modulators for Alzheimer&#39;s disease is fraught with challenges, the potential for more selective and effective therapies remains promising. Ongoing research into the structural biology of gamma secretase and the mechanistic understanding of A\u03b2 production will be vital in overcoming these hurdles and advancing therapeutic options for patients.</p>
</li>
<p>De Strooper, Bart, and Eric Karran. &quot;New Precision Medicine Avenues to the Prevention of Alzheimer&#39;s Disease from Insights into the Structure and Function of γ-Secretases.&quot; <em>The EMBO Journal</em>, vol. 43, no. 1, 2024, doi:10.1038/s44318-024-00057-w. Accessed 2024.</p>

<h2>Target Assessment Strategy for Gamma Secretase in Alzheimer&#39;s Disease</h2>

<h3>Overview</h3>

<p>The aim of this Target Assessment (TA) to Lead Identification (LI) plan is to evaluate gamma secretase as a therapeutic target in Alzheimer&#39;s disease (AD) over the course of one year. Given the critical role of gamma secretase in the production of amyloid-beta (Aβ) peptides, which are implicated in AD pathology, this strategy will focus on understanding the feasibility of targeting this enzyme to reduce Aβ production and aggregation.</p>

<h3>Key Inflection Points</h3>

<ol>
    <li><strong>Initial Feasibility Assessment</strong>: The first three months will involve a comprehensive literature review and expert consultations to assess the current understanding of gamma secretase&#39;s structure and function, particularly its allosteric modulation. Insights from recent cryo-EM structures will be pivotal in guiding the selection of compounds that stabilize the enzyme-substrate complex (De Strooper and Karran, 2024).</li>
    <li><strong>In Vitro Platform Development</strong>: Following the feasibility assessment, the next phase will focus on developing robust in vitro assay systems to evaluate the pharmacological properties of gamma secretase allosteric stabilizers (GSAS). This includes establishing assays to measure Aβ peptide levels and enzyme activity, ensuring that they align with the required pharmacological profiles (De Strooper and Karran, 2024).</li>
    <li><strong>Translational In Vivo Models</strong>: By the six-month mark, the project will transition to identifying suitable in vivo models that can provide mechanistic insights into gamma secretase function. This will involve evaluating models that reflect the physiological role of gamma secretase in neuronal signaling and its impact on Aβ processing. The focus will be on ensuring these models can adequately mimic the effects of potential GSAS compounds.</li>
</ol>

<h3>Challenges and Tractability</h3>

<p>One of the major challenges in advancing this project is the historical difficulty in establishing an acceptable efficacy/side effect therapeutic window for gamma secretase inhibitors (GSIs). Previous GSIs have faced significant setbacks due to adverse effects on normal physiological processes, particularly concerning Notch signaling (De Strooper and Karran, 2024). Therefore, the development of GSAS, which allow for normal physiological processing while favoring shorter Aβ peptides, offers a more tractable path forward.</p>

<h3>Biomarkers and Readouts for Efficacy</h3>

<p>To assess target engagement and the efficacy of gamma secretase modulation, the following biomarkers and readouts will be established:</p>

<ol>
    <li><strong>Cerebrospinal Fluid (CSF) Biomarkers</strong>: Monitoring changes in CSF levels of Aβ peptides, particularly the ratios of Aβ42 to Aβ40, will be crucial for verifying drug-target engagement (Lewczuk et al., 2017).</li>
    <li><strong>Plasma Biomarkers</strong>: The exploration of plasma biomarkers such as pTau231 could provide additional insights into the effects of gamma secretase modulation on neurodegeneration and cognitive function (Jack et al., 2023).</li>
    <li><strong>Functional Assessments</strong>: Behavioral and cognitive assessments in in vivo models will complement biomarker analyses, providing a holistic view of the therapeutic impact of gamma secretase modulation.</li>
</ol>

<p>In conclusion, this one-year TA to LI plan aims to systematically evaluate gamma secretase as a target for AD therapy, leveraging recent advancements in understanding its biology and pharmacology. By focusing on the development of GSAS and establishing robust in vitro and in vivo models, the project seeks to address historical challenges and pave the way for effective therapeutic interventions in Alzheimer&#39;s disease.</p>

<p><strong>Hur, Ji-Yeun.</strong> &quot;γ-Secretase in Alzheimer’s Disease.&quot; <em>Experimental &amp; Molecular Medicine</em>, vol. 54, no. 11, 2022, Article 9076685, doi:10.1038/s12276-022-00754-8. Accessed 2024.<p>

<p>Zhang, Yun, et al. &quot;Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future.&quot; <em>Signal Transduction and Targeted Therapy</em>, vol. 8, no. 1, 2023, Article 109, doi:10.1038/s41392-023-01484-7. Accessed 2024.<p>

<p>Imran, Khan, et al. “Efficient Production of a Mature and Functional Gamma Secretase Protease.” <em>Scientific Reports</em>, vol. 8, no. 1, 2018, article 12692. Nature Publishing Group, doi:10.1038/s41598-018-30788-w. Accessed 2024.<p>

<p><h3> Target Information </h3><p>



<p><strong>Expression Bias and Specificity</strong><br>The gamma secretase complex is predominantly expressed in the central nervous system (CNS), particularly in the brain, where it plays a crucial role in cleaving amyloid precursor protein (APP) to produce amyloid-beta (Aβ) peptides, which aggregate to form plaques—a hallmark of Alzheimer&#39;s disease (AD) (Hur, 2022). The specific expression of gamma secretase in the brain makes it a suitable target for therapeutic intervention in AD.<p>

<p><strong>Disease-Specific Expression Databases</strong><br>There are databases that focus on the expression profiles of genes in various diseases, including AD. These databases can provide insights into the expression levels of gamma secretase in AD patients compared to healthy individuals, highlighting its potential role in disease progression (Zhang et al., 2023).<p>

<p><strong>Tissue-Selective and Condition-Specific Isoforms</strong><br>While gamma secretase is primarily expressed in the brain, studies suggest that there may be tissue-selective isoforms, although the predominant form in the CNS is the one involved in Aβ production. Additionally, alternative splicing may lead to condition-specific isoforms that could influence gamma secretase activity under pathological conditions (Imran et al., 2018).<p>

<p><strong>Regulation of Alternative Splicing</strong><br>The regulation of alternative splicing that leads to different isoforms of gamma secretase is influenced by various factors, including cellular stress and environmental signals. Understanding these regulatory mechanisms is essential for developing targeted therapies that modulate specific isoforms without affecting others.<p>

<p><strong>Expression Levels in Mouse Models</strong><br>In vivo studies using mouse models of AD have demonstrated significant expression of gamma secretase, although the exact levels can vary based on the model used. These models are critical for assessing the functional role of gamma secretase in Aβ production and the overall pathogenesis of AD (Hur, 2022).<p>

<p><strong>Phenotypes in Knockout Models</strong><br>Major phenotypes have been reported in gamma secretase knockout models, including severe neurodevelopmental defects and altered Notch signaling, which underscores the enzyme&#39;s critical role in both AD and normal physiological processes (Hur, 2022).<p>

<p><strong>Differences in Expression Between Human and Rodent Models</strong><br>Published studies indicate differences in gamma secretase expression and activity between human and rodent models. This disparity can complicate the interpretation of safety data from rodent studies and necessitates careful consideration when extrapolating findings to humans (Zhang et al., 2023).<p>

<p><strong>Species Differences for Safety Data Interpretation</strong><br>Species differences in gamma secretase function and substrate specificity may influence the safety and efficacy of potential AD therapies. Understanding these differences is crucial for accurately interpreting the results from rodent models and their relevance to human AD (Imran et al., 2018).<p>

<p><strong>Peripheral Safety Risks and Oncogenesis</strong><br>Inhibition of gamma secretase can raise concerns regarding peripheral safety risks, particularly the potential for oncogenesis due to the disruption of Notch signaling, which is vital for cell differentiation and proliferation (Zhang et al., 2023). Modulation of gamma secretase activity could inadvertently promote tumor formation if Notch signaling is significantly disrupted.<p>

<p><strong>Assessing On-Target Safety Concerns</strong><br>On-target safety concerns can be assessed through comprehensive pharmacological studies that evaluate the effects of gamma secretase modulation on various substrates. This includes monitoring for adverse effects on Notch signaling and other critical pathways (Hur, 2022).<p>

<p><strong>Exaggerated Pharmacology Risks</strong><br>Exaggerated pharmacology may lead to severe disruptions in cellular functions, including those related to endosomal and lysosomal pathways, which could have significant safety liabilities (Zhang et al., 2023). <p>

<p><strong>Immunogenicity Risks</strong><br>The risk for immunogenicity, particularly in biologics or antibody-based approaches targeting gamma secretase, is a consideration that must be addressed during drug development, as it could lead to adverse immune responses.<p>

<p><strong>Polymorphisms Affecting Enzyme Activity</strong><br>Polymorphisms in the human gene encoding gamma secretase could alter its enzymatic activity, potentially influencing the efficacy and safety of therapeutic interventions aimed at modulating its function (Zhang et al., 2023). <p>

<p>Overall, targeting gamma secretase presents a promising avenue for reducing Aβ production in Alzheimer&#39;s disease, but it requires a thorough understanding of its complex biology and the potential risks associated with modulation.<p>

<p>

</ul>
</body></html>
</body></html>